Abstract 101: The Continuous Administration of Sevoflurane Protects the Heart Against Ischemic Injury via Distinct Mitochondrial Mechanisms

• Published in: Circulation research 2013-08, Vol.113 (suppl_1)
• Main Authors: Lotz, Christopher, Tischer-Zeitz, Tobias, Frank, Anja, Stumpner, Jan, Roewer, Norbert, Smul, Thorsten M
• Format: Article
• Language: English
• ISSN: 0009-7330; 1524-4571
• DOI: 10.1161/res.113.suppl_1.A101

Abstract only Sevoflurane induced cardioprotection against ischemia/reperfusion (I/R) injury represents a well-established phenomenon. Salutary effects of the volatile anesthetic are not only limited to pre- or post-ischemic use, but clinical data also indicate its continuous administration as a beneficial mean. We investigated the hypothesis that the administration of sevoflurane during I/R-injury results in cardioprotection via the recruitment of distinct mitochondrial mechanisms. After IRB approval New Zealand White rabbits (9-12 weeks of age) received sevoflurane (1.0 MAC) or propofol (10 mg/kg/h) during 30 min of coronary artery occlusion followed by 3 h of reperfusion (n=7 per group). Cardiac mitochondria were isolated at the end of reperfusion. TTC-staining was used to determine the myocardial infarct size; in addition, mitochondrial O2 consumption was quantified and expressed as the respiratory control ratio (RCR). Mitochondrial electron transport chain (ETC) complex activities (I-IV) were assayed; including the analysis of an active to dormant (A/D) ratio of complex I. Statistics: ANOVA followed by posthoc Bonferroni, Mean ± SD. Our data indicate a significant infarct size reduction in animals receiving sevoflurane throughout the I/R-injury (p